Lisa Cunningham
Family · Deland, FLNPI 1033534284
Payments from drug & device makers
Across 177 payments — averaging $71.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$4K
- Johnson & Johnson$2K
- Medtronic$1K
- Janssen Global Services, LLC$1K
- Myriad Genetic Laboratories, Inc.$747
- Dendreon Pharmaceuticals LLC$505
- plus $2K from 31 others
What the payments were for
- Consulting fees$2,06016%
- Speaking & faculty fees$3,67329%
- Travel & lodging$1,1219%
- Food & beverage$5,58144%
- Education$1871%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 18 | $4,444 |
| Johnson & Johnson(3 entities) | 20 | $2,133 |
| Medtronic | 25 | $1,224 |
| Janssen Global Services, LLC | 1 | $1,160 |
| Myriad Genetic Laboratories, Inc. | 22 | $747 |
| Dendreon Pharmaceuticals LLC | 9 | $505 |
| Endo Pharmaceuticals Inc. | 19 | $427 |
| Procept Biorobotics Corporation | 2 | $299 |
| AbbVie | 4 | $252 |
| Tempus AI, Inc | 3 | $130 |
| Amgen | 1 | $125 |
| Myovant Sciences Inc. | 5 | $102 |
| Tolmar Pharmaceuticals, Inc. | 5 | $96 |
| Sun Pharmaceutical Industries Inc. | 5 | $94 |
| Novartis | 4 | $89 |
| Astellas Pharma US Inc | 1 | $87 |
| Sumitomo Pharma America, Inc. | 3 | $82 |
| Endo USA, Inc. | 3 | $70 |
| Teleflex LLC | 3 | $63 |
| Ferring Pharmaceuticals Inc. | 2 | $42 |
| Coloplast | 1 | $40 |
| Accord Healthcare, Inc. | 2 | $39 |
| Verity Pharmaceuticals Inc. | 2 | $38 |
| Janssen Scientific Affairs, LLC | 1 | $38 |
| Bioprotect Medical, Inc. | 2 | $35 |
| Blue Earth Diagnostics | 2 | $33 |
| Antares Pharma, Inc. | 2 | $32 |
| Eagle Pharmaceuticals, Inc. | 1 | $26 |
| Novo Nordisk | 1 | $23 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $23 |
| Axonics, Inc. | 1 | $22 |
| Calyxo, Inc. | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Olympus America Inc. | 1 | $18 |
| Telix Pharmaceuticals | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,622 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 85 | $64,552 |
| GemtesaVibegron | 59 | $60,257 |
| Solifenacin Succinate | 138 | $9,258 |
| Tamsulosin Hcl | 437 | $7,680 |
| Estradiol | 90 | $4,981 |
| Silodosin | 44 | $2,625 |
| Methenamine Hippurate | 24 | $2,291 |
| Finasteride | 145 | $1,726 |
| Tolterodine Tartrate ErTolterodine Tartrate | 20 | $1,477 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 16 | $1,396 |
| NitrofurantoinNitrofurantoin Macrocrystal | 17 | $804 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 33 | $759 |
| Cephalexin | 54 | $598 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $265 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $87 | $64,55285 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $82 | $60,25759 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Deland
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.